{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:53:53Z","timestamp":1791258833208,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xphs.2026.104517","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:23:58Z","timestamp":1790436238000},"page":"104517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Process reagent clearance for biopharmaceutical products: A science-based perspective incorporating safety threshold limits and clearance modeling"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6003-6687","authenticated-orcid":false,"given":"Pengxiao","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Koon","family":"Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-465X","authenticated-orcid":false,"given":"Soumitra","family":"Bhoyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun F.","family":"Ozbakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-4051","authenticated-orcid":false,"given":"Jeanine","family":"Bussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9965","authenticated-orcid":false,"given":"Shawn","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2026.104517_bib0001","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5731\/pdajpst.2015.01056","article-title":"Risk-based strategy to determine testing requirement for the removal of residual process reagents as process-related impurities in bioprocesses","volume":"69","author":"Qiu","year":"2015","journal-title":"PDA J Pharm Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104517_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3119","article-title":"Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: categorization, risk assessment, testing strategy, and process development with leveraging clearance potential","volume":"37","author":"Luo","year":"2021","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104517_bib0003","unstructured":"U.S. Food and Drug Administration. Inactive ingredients database. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/inactive-ingredients-database-download. Accessed Feb 2, 2026."},{"issue":"2","key":"10.1016\/j.xphs.2026.104517_bib0004","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jpen.2306","article-title":"ASPEN Parenteral Nutrition Safety Committee. Parenteral nutrition compatibility and stability: a comprehensive review","volume":"46","author":"Boullata","year":"2022","journal-title":"J Parenteral Enteral Nutr"},{"key":"10.1016\/j.xphs.2026.104517_bib0005","unstructured":"International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. Guideline Elemental Impurities Q3D(R2). Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q3D-R2_Guideline_Step4_2022_0308.pdf. Accessed Feb 2, 2026."},{"issue":"D1","key":"10.1016\/j.xphs.2026.104517_bib0006","doi-asserted-by":"crossref","first-page":"D608","DOI":"10.1093\/nar\/gkx1089","article-title":"HMDB 4.0: the human metabolome database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"10.1016\/j.xphs.2026.104517_bib0007","doi-asserted-by":"crossref","first-page":"D521","DOI":"10.1093\/nar\/gkl923","article-title":"HMDB: the human metabolome database","volume":"35","author":"Wishart","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xphs.2026.104517_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104524","article-title":"Qualification of impurities based on metabolite data","volume":"110","author":"Weidolf","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2026.104517_bib0009","unstructured":"International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. Guideline Residual Solvents Q3C(R9). Available at: https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf. Accessed Feb 23, 2026."},{"issue":"1","key":"10.1016\/j.xphs.2026.104517_bib0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.yrtph.2012.08.002","article-title":"Advancing toxicology in RiskMAPP: setting ADEs based on the subsequent drug substance","volume":"65","author":"Bercu","year":"2013","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2026.104517_bib0011","article-title":"A-Mab: A Case Study in Bioprocess Development. Version 2.1","year":"2009","journal-title":"CASSS\/ISPE"},{"key":"10.1016\/j.xphs.2026.104517_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114249","article-title":"Method development for the clearance study of the Pluronic F-68 nonionic surfactant used in the upstream process of monoclonal antibody production","volume":"204","author":"S\u00e1voly","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2026.104517_bib0013","unstructured":"International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities New Drug Substances Q3A(R2). Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q3A%28R2%29%20Guideline.pdf. Accessed Feb 2, 2026."},{"key":"10.1016\/j.xphs.2026.104517_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.memsci.2022.120333","article-title":"Modeling the Gibbs\u2013Donnan effect during ultrafiltration and diafiltration processes using the Poisson\u2013Boltzmann theory in combination with a basic Stern model","volume":"648","author":"Briskot","year":"2022","journal-title":"J Membr Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104517_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3106","article-title":"A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration\/diafiltration process of protein formulations","volume":"37","author":"Yu","year":"2021","journal-title":"Biotechnol Prog"},{"issue":"5","key":"10.1016\/j.xphs.2026.104517_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.2993","article-title":"Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies","volume":"36","author":"Ladwig","year":"2020","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104517_bib0017","unstructured":"International Council for Harmonisation (ICH) of technical requirements for pharmaceuticals for human use. Nonclinical Saf Test Support Dev Paediatric Pharmaceuticals S11. Available at: https:\/\/database.ich.org\/sites\/default\/files\/S11_Step4_FinalGuideline_2020_0310.pdf. Accessed Mar 26, 2026."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:43:09Z","timestamp":1791258189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0022354926003679"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104517","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Process reagent clearance for biopharmaceutical products: A science-based perspective incorporating safety threshold limits and clearance modeling","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104517"}}